Nasal Discharge — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for nasal discharge. 6 active patents protecting 2 drugs from 2+ originators. First major cliff: 2027. Daily refresh.

2
Approved drugs
6
Active US patents
61/100
Avg vulnerability
—
Annual revenue covered

Originators in Nasal Discharge

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Bayer 3 patents Generic (multiple manufacturers) 3 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating nasal discharge. Each bar = one year. Y-axis scaled to peak year (3 patents).

1
27
2
32
3
35

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Tussionex Pennkinetic
CHLORPHENIRAMINE MALEATE
 Bayer 3 60 — 2027-02-28
Mucinex
guaifenesin
 Generic (multiple manufacturers) 3 62 — 2035-11-13

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
9066942 Tussionex Pennkinetic method of use 68 2032-01-03
7863287 Tussionex Pennkinetic formulation 65 2027-02-28
10105324 Mucinex method of use 62 2035-11-13
9549907 Mucinex method of use 62 2035-11-13
9808431 Mucinex method of use 62 2035-11-13
9107921 Tussionex Pennkinetic formulation 48 2032-01-03

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
9107921 Tussionex Pennkinetic formulation 48 2032-01-03
10105324 Mucinex method of use 62 2035-11-13
9549907 Mucinex method of use 62 2035-11-13
9808431 Mucinex method of use 62 2035-11-13
7863287 Tussionex Pennkinetic formulation 65 2027-02-28
9066942 Tussionex Pennkinetic method of use 68 2032-01-03

Related